Legend Biotech Corporation LEGN

Updated: 11 Aug 2026

NASDAQ | Biotech | Cell therapy and biotechnology

No signal published yet

We already track Legend Biotech and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Legend Biotech free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Cell therapy and biotechnology
We're already tracking Legend Biotech Corporation — here are the latest events we've registered

Recent News

  • In July 2026, Legend Biotech announced a leadership transition appointing Alan Bash as interim CEO effective July 24, 2026, following the departure of Ying Huang. Earlier in June 2026, the company completed a public offering of American Depositary Shares, raising approximately $225 million in gross proceeds.

What Firelda Watch includes for Legend Biotech Corporation

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Legend Biotech Corporation will be delivered in the same format.

Want to follow Legend Biotech Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Legend Biotech free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Legend Biotech Corporation LEGN
Legend Biotech — follow and we'll monitor it
Follow Legend Biotech free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.